Fludarabine/Cyclophosphamide Conditioning Regimen in Aplastic Anemia Patients Receiving Matched-Sibling Donor Transplant Is Non-inferior to ATG/Cyclophosphamide: A Single-Center Experience from Pakistan
Table 3
Univariate analysis of influenced factors for overall survival (OS), GvHD-free survival (GFS), and relapse-free survival (RFS).
Variable
OS
GFS
RFS
Median (IIQR)
value
Median (IQR)
value
Median (IIQR)
value
Time diagnosis to transplant (months)
3 (2-4)
0.265
3 (2-4)
0.434
3 (2-4)
0.242
n (%)
n (%)
n (%)
Age group
<18years
58 (60.4)
0.687
51 (62.2)
0.539
55 (59.8)
0.839
≥18 years
38 (39.6)
31 (37.8)
37 (40.2)
Gender
Male
67 (69.8)
0.668
69 (84.1)
0.507
64 (69.6)
0.668
Female
29 (30.2)
23 (28.0)
28 (30.4)
Gender mismatch
Female to male
15 (15.6)
0.779
13 (15.9)
0.774
14 (15.2)
0.778
Same
81 (84.4)
60 (64.5)
78 (84.8)
Conditioning
Flu/Cy
67 (69.8)
0.401
55 (67.1)
0.579
64 (69.6)
0.521
ATG/Cy
29 (30.2)
27 (32.9)
28 (30.4)
Disease category
SAA
88 (91.7)
0.110
74 (90.2)
0.103
85 (92.4)
0.188
VSAA
8 (8.3)
8 (9.8)
7 (7.6)
Cyclosporine use
Yes
87 (90.6)
0.126
74 (90.2)
0.134
83 (90.2)
0.133
No
9 (9.4)
8 (9.8)
9 (9.8)
CD34
<2.6
11 (11.5)
0.008
9 (11.0)
0.008
11 (12.0)
0.010
≥2.6
85 (88.5)
73 (89.0)
81 (88.0)
TNC
17 (17.7)
0.050
14 (17.1)
0.049
16 (17.4)
0.001
79 (82.3)
68 (82.9)
76 (82.6)
Graft source
PB
62 (64.6)
0.427
53 (64.6)
0.498
60 (65.2)
0.443
BM
25 (26.0)
21 (25.6)
23 (25.0)
PB/BM
9 (9.4)
8 (9.8)
9 (9.8)
Primary graft failure
Yes
3 (3.1)
<0.001
3 (3.7)
<0.001
2 (2.2)
<0.001
No
93 (96.9)
79 (96.3)
90 (97.8)
Secondary graft failure
Yes
6 (6.2)
0.001
6 (7.3)
0.006
4 (4.3)
<0.001
No
90 (93.8)
76 (92.7)
88 (95.7)
value calculated by using chi-square test and Fisher’s exact test.
